thalidomide has been researched along with Central Nervous System Neoplasm in 15 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of pomalidomide (POM) and dexamethasone (DEX) was evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL) to determine the maximal tolerated dose (MTD) of POM as the primary objective, and overall response rate (ORR), progression-free survival (PFS), and safety profile as secondary objectives." | 9.27 | Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. ( Atherton, PJ; DeAngelis, LM; Grommes, C; Jaeckle, KA; Johnston, PB; Koenig, PA; O'Neill, B; Omuro, AMP; Pederson, LD; Pulido, J; Reeder, CB; Schiff, D; Tun, HW; Witzig, TE, 2018) |
| " Thalidomide, an antiangiogenic agent, may play a role in the treatment of glioblastoma multiforme (GBM)." | 9.13 | A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. ( Cole, BF; Eskey, CJ; Fadul, CE; Kingman, LS; Meyer, LP; Newton, HB; Pipas, JM; Rhodes, CH; Roberts, DW, 2008) |
| "Pomalidomide (POM) is a novel immunomodulatory drug with anti-lymphoma activity." | 5.39 | Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. ( Babusis, D; Copland, JA; Edenfield, B; Huang, P; Katz, J; Li, Z; Moghaddam, MF; Personett, D; Qiu, Y; Shirely, MA; Tang, Y; Tun, HW, 2013) |
| "The combination of pomalidomide (POM) and dexamethasone (DEX) was evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL) to determine the maximal tolerated dose (MTD) of POM as the primary objective, and overall response rate (ORR), progression-free survival (PFS), and safety profile as secondary objectives." | 5.27 | Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. ( Atherton, PJ; DeAngelis, LM; Grommes, C; Jaeckle, KA; Johnston, PB; Koenig, PA; O'Neill, B; Omuro, AMP; Pederson, LD; Pulido, J; Reeder, CB; Schiff, D; Tun, HW; Witzig, TE, 2018) |
| " Thalidomide, an antiangiogenic agent, may play a role in the treatment of glioblastoma multiforme (GBM)." | 5.13 | A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. ( Cole, BF; Eskey, CJ; Fadul, CE; Kingman, LS; Meyer, LP; Newton, HB; Pipas, JM; Rhodes, CH; Roberts, DW, 2008) |
| "Although multiple myeloma (MM) remains an incurable disease, considerable improvements in survival have been made with the introduction of autologous stem cell transplantation and new drugs." | 2.77 | Emergence of central nervous system myeloma in the era of novel agents. ( Carney, DA; Gangatharan, SA; Harrison, SJ; Januszewicz, EH; Prince, HM; Ritchie, DS; Wolf, MM, 2012) |
| "Lenalidomide was administered by mouth daily for 21 days, repeated every 28 days." | 2.76 | Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. ( Blaney, SM; Boyett, JM; Fangusaro, J; Goldman, S; Jakacki, R; Kun, LE; Macdonald, T; Packer, R; Pollack, IF; Schaiquevich, P; Stewart, CF; Wallace, D; Warren, KE, 2011) |
| "Pomalidomide (POM) is a novel immunomodulatory drug with anti-lymphoma activity." | 1.39 | Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. ( Babusis, D; Copland, JA; Edenfield, B; Huang, P; Katz, J; Li, Z; Moghaddam, MF; Personett, D; Qiu, Y; Shirely, MA; Tang, Y; Tun, HW, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Oka, S | 1 |
| Ono, K | 1 |
| Nohgawa, M | 1 |
| Gupta, NK | 1 |
| Wang, CC | 1 |
| Mannis, GN | 1 |
| Yu, JJ | 1 |
| Rubenstein, JL | 1 |
| Tun, HW | 3 |
| Johnston, PB | 1 |
| DeAngelis, LM | 1 |
| Atherton, PJ | 1 |
| Pederson, LD | 1 |
| Koenig, PA | 1 |
| Reeder, CB | 1 |
| Omuro, AMP | 1 |
| Schiff, D | 1 |
| O'Neill, B | 1 |
| Pulido, J | 1 |
| Jaeckle, KA | 1 |
| Grommes, C | 2 |
| Witzig, TE | 1 |
| Nayak, L | 1 |
| Batchelor, TT | 1 |
| Abdallah, AO | 1 |
| Atrash, S | 1 |
| Muzaffar, J | 1 |
| Abdallah, M | 1 |
| Kumar, M | 1 |
| Van Rhee, F | 1 |
| Barlogie, B | 2 |
| Li, Z | 1 |
| Qiu, Y | 1 |
| Personett, D | 1 |
| Huang, P | 1 |
| Edenfield, B | 1 |
| Katz, J | 1 |
| Babusis, D | 1 |
| Tang, Y | 1 |
| Shirely, MA | 1 |
| Moghaddam, MF | 1 |
| Copland, JA | 1 |
| Houillier, C | 1 |
| Choquet, S | 1 |
| Touitou, V | 1 |
| Martin-Duverneuil, N | 1 |
| Navarro, S | 1 |
| Mokhtari, K | 1 |
| Soussain, C | 1 |
| Hoang-Xuan, K | 1 |
| Fadul, CE | 1 |
| Kingman, LS | 1 |
| Meyer, LP | 1 |
| Cole, BF | 1 |
| Eskey, CJ | 1 |
| Rhodes, CH | 1 |
| Roberts, DW | 1 |
| Newton, HB | 1 |
| Pipas, JM | 1 |
| Warren, KE | 1 |
| Goldman, S | 1 |
| Pollack, IF | 1 |
| Fangusaro, J | 1 |
| Schaiquevich, P | 1 |
| Stewart, CF | 1 |
| Wallace, D | 1 |
| Blaney, SM | 1 |
| Packer, R | 1 |
| Macdonald, T | 1 |
| Jakacki, R | 1 |
| Boyett, JM | 1 |
| Kun, LE | 1 |
| Cox, MC | 1 |
| Mannino, G | 1 |
| Lionetto, L | 1 |
| Naso, V | 1 |
| Simmaco, M | 1 |
| Spiriti, MA | 1 |
| Gangatharan, SA | 1 |
| Carney, DA | 1 |
| Prince, HM | 1 |
| Wolf, MM | 1 |
| Januszewicz, EH | 1 |
| Ritchie, DS | 1 |
| Harrison, SJ | 1 |
| Mussetti, A | 1 |
| Dalto, S | 1 |
| Montefusco, V | 1 |
| Gertz, MA | 1 |
| Fine, HA | 1 |
| Kim, L | 1 |
| Albert, PS | 1 |
| Duic, JP | 1 |
| Ma, H | 1 |
| Zhang, W | 1 |
| Tohnya, T | 1 |
| Figg, WD | 1 |
| Royce, C | 1 |
| Fassas, AB | 1 |
| Muwalla, F | 1 |
| Berryman, T | 1 |
| Benramdane, R | 1 |
| Joseph, L | 1 |
| Anaissie, E | 1 |
| Sethi, R | 1 |
| Desikan, R | 1 |
| Siegel, D | 1 |
| Badros, A | 1 |
| Toor, A | 1 |
| Zangari, M | 1 |
| Morris, C | 1 |
| Angtuaco, E | 1 |
| Mathew, S | 1 |
| Wilson, C | 1 |
| Hough, A | 1 |
| Harik, S | 1 |
| Tricot, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of Pomalidomide for Patients With Relapsed/Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma[NCT01722305] | Phase 1 | 29 participants (Actual) | Interventional | 2013-04-08 | Completed | ||
| A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects[NCT01707407] | Phase 1 | 32 participants (Actual) | Interventional | 2012-09-01 | Completed | ||
| A Phase II Study Of Thalidomide And CPT-11 (IRINOTECAN) Following Radiotherapy For Glioblastoma Multiforme[NCT00039468] | Phase 2 | 26 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| A Phase I Trial Of A Thalidomide Analog, CC-5013, For The Treatment Of Patients With Recurrent High-Grade Gliomas[NCT00036894] | Phase 1 | 0 participants | Interventional | 2002-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for thalidomide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; | 2019 |
Successful treatment of Bing-Neel syndrome using intrathecal chemotherapy and systemic combination chemotherapy followed by BEAM auto-transplant: a case report and review of literature.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2013 |
Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms | 2002 |
5 trials available for thalidomide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neopla | 2018 |
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neopla | 2018 |
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neopla | 2018 |
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neopla | 2018 |
A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Ne | 2008 |
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Area Under Curve; Central Nervous System Ne | 2011 |
Emergence of central nervous system myeloma in the era of novel agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nerv | 2012 |
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Central Nervous System Neoplasms; Dose-Respon | 2007 |
7 other studies available for thalidomide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Successful treatment with pomalidomide and intrathecal injections for central nervous system plasmacytoma in a patient under haemodialysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophospha | 2020 |
Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretro | 2017 |
Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.
Topics: Angiogenesis Inhibitors; Animals; Cells, Cultured; Central Nervous System Neoplasms; Disease Models, | 2013 |
Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma.
Topics: Aged; Angiogenesis Inhibitors; Central Nervous System Neoplasms; Female; Humans; Lenalidomide; Lymph | 2015 |
Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?
Topics: Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chromatography, Liquid; Humans; Lenal | 2011 |
Effective treatment of pomalidomide in central nervous system myelomatosis.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Male; Middle Aged; Multiple Myeloma | 2013 |
Pomalidomide and myeloma meningitis.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Male; Multiple Myeloma; Thalidomide | 2013 |